Class: Antiallergic Agents
ATC Class: S01GX05
VA Class: OP900
Chemical Name: N,N′-2-(chloro-5-cyano-m-phenylene)dioxamic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)
Molecular Formula: C11H6ClN3O6•2C4H11NO3
CAS Number: 63610-09-3
Uses for Lodoxamide Tromethamine
Allergic Ocular Disorders
Lodoxamide Tromethamine Dosage and Administration
Avoid contamination of the solution container.1
Available as lodoxamide tromethamine; dosage expressed in terms of lodoxamide.1
Allergic Ocular Disorders
Allergic Ocular Disorders
Cautions for Lodoxamide Tromethamine
Known hypersensitivity to lodoxamide or any ingredient in the formulation.a
Possible ocular burning or stinging upon installation.a (See Advice to Patients.)
Safety and efficacy not established in children <2 years of age.1
No substantial differences in safety and efficacy relative to younger adults.a
Common Adverse Effects
Ocular burning, stinging, discomfort.a
Lodoxamide Tromethamine Pharmacokinetics
Plasma concentrations are undetectable following topical application to the eye.1
Not known whether lodoxamide is distributed into milk.a
Excreted principally in urine after oral administration.a
8.5 hours following oral administration.a
Advice to Patients
Importance of learning and adhering to proper administration techniques to avoid contamination of the product.a
Importance of not wearing soft contact lenses during therapy (since benzalkonium chloride preservative may be absorbed by the lenses).a
Importance of contacting clinician if burning or stinging experienced during instillation persists.a
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a
Importance of informing patients of other important precautionary information.a (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
0.1% (of lodoxamide)
Alomide (with benzalkonium chloride)
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2013. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Alomide 0.1% Solution (ALCON VISION): 10/$114.41 or 30/$333.43
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2013, Selected Revisions August 1, 2005. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Alcon. Alomide (lodoxamide ophthalmic solution) 0.1% prescribing information. Fort Worth, TX; 1993 Nov.
2. Caldwell DR, Verin P, Hartwich-Young R et al. Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am J Ophthalmol. 1992; 113:632-7. [IDIS 297902] [PubMed 1598953]
3. Food and Drug Administration. Orphan designations pursuant to section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414), to June 30, 1993. Rockville, MD; 1993 Jul.
4. Yanni JM, Weimer LK, Glaser RL et al. Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats. Int Arch Allergy Immunol. 1993; 101:102-6. [PubMed 7684628]
5. Alcon, Fort Worth, TX: Personal communication.
6. Anon. Lodoxamide for vernal keratoconjunctivitis. Med Lett Drugs Ther. 1994; 36:26. [PubMed 8121328]
7. Santos CI, Huang AJ, Abelson MB et al. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol. 1994; 117:488-97. [IDIS 328164] [PubMed 8154531]
a. Alcon. Alomide (lodoxamide ophthalmic solution) 0.1% prescribing information. Fort Worth, TX; 2003.